Invivoscribe Technologies

Company Overview: Invivoscribe Technologies, Inc., with headquarters in San Diego, California, is a leading provider of clinically validated personalized molecular diagnostics. The company and its subsidiaries provide one stop comprehensive care for patients in over 50 countries. Invivoscribe's portfolio of products include a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls for the identification, classification and monitoring of leukemia, lymphomas and other lymphoproliferative diseases. Products include CE-marked IVD products for use outside North America, as well as a wide selection of Analyte Specific Reagents (ASRs), Research Use Only and General Laboratory Reagents.

Laboratory for Personalized Molecular Medicine (LabPMM), a fully owned subsidiary of Invivoscribe, is CLIA- and CAP-accredited reference laboratory that provides services focused on Personalized Molecular Medicine™, Personalized Molecular Diagnostics™, and biomarker testing. LabPMM has testing facilities in San Diego, California (LabPMM LLC) and Martinsried, Germany (LabPMM GmbH). These are the only clinical laboratories outside of Japan licensed to perform FLT3 biomarker testing and the only laboratories in the world licensed to determine the mutation status of both FLT3 and NPM1.


Invivoscribe Technologies

6330 Nancy Ridge Dr. Ste 106
CA 92121 San Diego
Vereinigte Staaten von Amerika
Klinische Forschung